Targeting Keap1/Nrf2/ARE signaling pathway in multiple sclerosis

Area of Science:

• Neuroimmunology
• Oxidative Stress Research
• Pharmacology

Background:

• Multiple sclerosis (MS) involves central nervous system inflammation, demyelination, and axonal damage.
• Oxidative stress (OS) exacerbates MS pathology by damaging cellular components and promoting neuroinflammation.
• The Keap1/Nrf2/ARE pathway is a key regulator of antioxidant and inflammatory responses, implicated in MS pathogenesis.

Purpose of the Study:

• To review current preclinical and clinical evidence on Nrf2 pathway induction for MS treatment.
• To explore the role of Nrf2 in restoring antioxidant capacity and mitigating inflammation in MS.
• To assess the therapeutic potential of Nrf2 activators in ameliorating MS symptoms.

Main Methods:

• Literature review of preclinical studies and clinical trials.
• Analysis of the mechanisms by which Nrf2 activators impact oxidative stress and inflammation in MS models.
• Evaluation of the efficacy and safety data for compounds targeting the Nrf2 pathway.

Main Results:

• Preclinical studies demonstrate that Nrf2 activators like EGCG, curcumin, melatonin, resveratrol, and sulforaphane show potential in ameliorating MS symptoms.
• These compounds may work by upregulating antioxidant defenses and suppressing pro-inflammatory responses.
• Evidence suggests the Nrf2 pathway's crucial role in managing the 'oxinflammation' cycle in MS.

Conclusions:

• Nrf2 pathway induction represents a promising therapeutic strategy for multiple sclerosis.
• Natural compounds activating Nrf2 warrant further investigation in clinical trials for MS treatment efficacy and safety.
• Targeting the Keap1/Nrf2/ARE pathway offers a novel approach to combatting neuroinflammation and oxidative stress in MS.